<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301233148
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Libsa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        192.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALPHA PHARMA INDUSTRY " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2732]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Alpha Pharma Industry
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>LIBSA</strong> contains the active substance rivaroxaban and is used in adults to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent blood clots in the veins after a hip or knee replacement operation. Your doctor has prescribed this medicine for you because after an operation you are at an increased risk of getting blood clots.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.</p><p><strong>LIBSA</strong> belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>LIBSA </strong><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are bleeding excessively</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver disease which leads to an increased risk of bleeding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding</p><p><strong>Do not take LIBSA and tell your doctor</strong> if any of these apply to you.<strong> </strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking <strong>LIBSA</strong>.</p><p><strong>Take special care with LIBSA &nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an increased risk of bleeding, as could be the case in situations such as:</p><p>&sect;&nbsp; moderate or severe kidney disease<strong>, </strong>since your kidney function may affect the amount of medicine that works in your body</p><p>&sect;&nbsp; if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section &ldquo;Other medicines and <strong>LIBSA</strong>&rdquo;)</p><p>&sect;&nbsp; bleeding disorders</p><p>&sect;&nbsp; very high blood pressure, not controlled by medical treatment</p><p>&sect;&nbsp; diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the esophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the esophagus) or tumors located in the stomach or bowels or genital tract or urinary tract</p><p>&sect;&nbsp; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>&sect;&nbsp; a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a prosthetic heart valve</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned.</p><p><strong>If any of the above apply to you, tell your doctor </strong>before you take <strong>LIBSA</strong>. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p><strong>If you need to have an operation </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important to take <strong>LIBSA </strong>before and after the operation exactly at the times you have been told by your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anesthesia or pain reduction):</p><p>&sect;&nbsp; it is very important to take <strong>LIBSA </strong>exactly at the times you have been told by your doctor</p><p>&sect;&nbsp; tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anesthesia, because urgent care is necessary.</p><p><strong>Children and adolescents </strong></p><p><strong>LIBSA </strong>10 mg tablets are <strong>not recommended for people under 18 years of age. </strong>There is not enough information on their use in children and adolescents.</p><p><strong>Other medicines and </strong><strong>LIBSA </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are taking </strong></p><p>&sect;&nbsp; some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin</p><p>&sect;&nbsp; ketoconazole tablets (used to treat Cushing&rsquo;s syndrome - when the body produces an excess of cortisol)</p><p>&sect;&nbsp; some medicines for bacterial infections (e.g. clarithromycin, erythromycin)</p><p>&sect;&nbsp; some anti-viral medicines for HIV / AIDS (e.g. ritonavir)</p><p>&sect;&nbsp; other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)</p><p>&sect;&nbsp; anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)</p><p>&sect;&nbsp; dronedarone, a medicine to treat abnormal heart beat</p><p>&sect;&nbsp; some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))</p><p><strong>If any of the above apply to you, tell your doctor </strong>before taking <strong>LIBSA</strong>, because the effect of <strong>LIBSA</strong> may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p>If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking</p><p>&sect;&nbsp; some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</p><p>&sect;&nbsp; St John&rsquo;s Wort (<em>Hypericum perforatum</em>), a herbal product used for depression</p><p>&sect;&nbsp; rifampicin, an antibiotic</p><p><strong>If any of the above apply to you, tell your doctor </strong>before taking <strong>LIBSA</strong>, because the effect of <strong>LIBSA </strong>may be reduced. Your doctor will decide, if you should be treated with <strong>LIBSA</strong> and if you should be kept under closer observation.</p><p><strong>LIBSA </strong><strong>with food and drink</strong></p><p><strong>LIBSA </strong>can be taken with or without food.</p><p><strong>Pregnancy, and breastfeeding </strong></p><p>Do not take <strong>LIBSA</strong> if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking <strong>LIBSA</strong>. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p><strong>Driving and using machines </strong></p><p><strong>LIBSA</strong> may cause dizziness (common side effect) or fainting (uncommon side effect) (see section &ldquo;4 Possible side effects&rdquo;). You should not drive, ride a bicycle or use any tools or machines if you are affected by these symptoms.</p><p><strong>LIBSA contains lactose and sodium</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains 0.262 mg sodium per tablet, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent blood clots in the veins after a hip or knee replacement operation</p><p>The recommended dose is one tablet <strong>LIBSA</strong> 10 mg once a day<strong>. </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring</p><p>After at least 6 months&rsquo; blood clot treatment, the recommended dose is either one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed you <strong>LIBSA</strong> 10 mg once a day.</p><p>Swallow the tablet preferably with water.</p><p><strong>LIBSA </strong>can be taken with or without food.</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take <strong>LIBSA</strong>. The tablet may be crushed and mixed with water or apple puree immediately before you take it.</p><p>If necessary, your doctor may also give you the crushed <strong>LIBSA </strong>tablet through a stomach tube.</p><p><strong>When to take LIBSA &nbsp;</strong></p><p>Take the tablet every day until your doctor tells you to stop.</p><p>Try to take the tablet at the same time every day to help you to remember it.</p><p>Your doctor will decide how long you must continue treatment.</p><p><u>To prevent blood clots in the veins after a hip or knee replacement operation: </u></p><p>Take the first tablet 6 - 10 hours after your operation.</p><p>If you have had a major hip operation you will usually take the tablets for 5 weeks.</p><p>If you have had a major knee operation you will usually take the tablets for 2 weeks.</p><p><strong>If you take more LIBSA than you should</strong></p><p>Contact your doctor immediately if you have taken too many <strong>LIBSA </strong>tablets. Taking too much <strong>LIBSA</strong> increases the risk of bleeding.</p><p><strong>If you forget to take </strong><strong>LIBSA </strong></p><p>If you have missed a dose, take it as soon as you remember. Take the next tablet on the following day and then carry on taking a tablet once a day as normal.</p><p>Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking </strong><strong>LIBSA </strong></p><p>Do not stop taking <strong>LIBSA </strong>without talking to your doctor first, because <strong>LIBSA </strong>prevents the development of a serious condition.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate in nature.</p><p>Like other similar medicines to reduce the formation of blood clots, <strong>LIBSA </strong>may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases, the bleeding may not be obvious.</p><p><strong>Tell your doctor immediately if you experience any of the following side effects:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of bleeding </strong></p><p>&sect;&nbsp; bleeding into the brain or inside the skull (symptoms can include headache, one-sided weakness, vomiting, seizures, decreased level of consciousness, and neck stiffness. A serious medical emergency. Seek medical attention immediately!</p><p>&sect;&nbsp; long or excessive bleeding</p><p>&sect;&nbsp; exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris</p><p>Your doctor may decide to keep you under closer observation or change the treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of severe skin reactions </strong></p><p>&sect;&nbsp; spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>&sect;&nbsp; a drug reaction that causes rash, fever, inflammation of internal organs, blood abnormalities and systemic illness (DRESS syndrome).</p><p>The frequency of these side effects is very rare (up to 1 in 10,000 people).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of severe allergic reactions </strong></p><p>&sect;&nbsp; Swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure.</p><p>The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).</p><p><strong>Overall list of possible side effects</strong></p><p><strong>Common </strong>(may affect more than or equal to 1 in 100 and less than 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the eye (including bleeding from the whites of the eyes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into tissue or a cavity of the body (hematoma, bruising)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the skin or under the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding following an operation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oozing of blood or fluid from surgical wound</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the limbs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the limbs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of the kidneys (may be seen in tests performed by your doctor)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache, indigestion, feeling or being sick, constipation, diarrhea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (symptoms may be feeling dizzy or fainting when standing up)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased general strength and energy (weakness, tiredness), headache, dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itchy skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in some liver enzymes</p><p><strong>&nbsp;Uncommon </strong>(may affect more than or equal to 1 in 1000 and less than 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the brain or inside the skull (see above, signs of bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into a joint causing pain and swelling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopenia (low number of platelets, which are cells that help blood to clot)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions, including allergic skin reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of the liver (may be seen in tests performed by your doctor)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; faster heartbeat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p><strong>Rare (</strong>may affect more or equal to 1 in 10,000 and less than 1 in 1,000 people<strong>)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into a muscle</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and eye (jaundice)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; localized swelling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collection of blood (hematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudo aneurysm)</p><p><strong>Frequency not known (</strong>cannot be estimated from the available data)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure after a severe bleeding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)</p><p>Ask your doctor or pharmacist for further information about the side effects.</p><p><strong>To report any side effect(s): </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the pack is changed or showing signs of tampering.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crushed tablets: are stable in water or apple puree for up to 4 hours.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the pack is changed or showing signs of tampering.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crushed tablets: are stable in water or apple puree for up to 4 hours.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LIBSA  10 mg film-coated tablets are pink, round shaped, biconvex film-coated tablets, debossed “JS51” on one side and plain on other side.
LIBSA  10 mg film-coated tablets are available in two pack sizes either containing 30 tablets or 10 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alpha Pharma,</p><p>King Abdullah Economic city, Kingdom of Saudi Arabia</p><p>Tel:&nbsp;+966 12 21 29013</p><p>Email: regulatory@alphapharma.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                4/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>ليبسا</strong> على المادة الفعالة ريفاروكسابان و يستخدم لدى البالغين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع حدوث التجلطات الدموية في الأوردة بعد عملية استبدال مفصل الورك أو الركبة. لقد وصف لك الطبيب هذا الدواء لأنه بعد العملية تزيد نسبة الاصابة بتجلطات دموية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التجلطات الدموية في أوردة الساق (تجلط وريدي عميق) و في الأوعية الدموية للرئة (الانسداد الرئوي)، و لمنع تكرار حدوث التجلطات الدموية في الأوعية الدموية للساق و/أو الرئة.</p><p dir="RTL">ينتمي <strong>ليبسا</strong> لمجموعة من الأدوية تسمى مضادات التخثر. وتعمل عن طريق منع عامل التجلط الدموي (عامل Xa)، بالتالي يقلل من قابلية الدم لتشكيل تجلط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ليبسا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية للريفاروكسابان أو لأي من المكونات الأخرى في هذا الدواء (المدونة في الجزء 6)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنزف بإفراط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض أو حالة مرضية في أحد أعضاء الجسم تزيد من خطر النزف الحاد (مثال لذلك قرحة المعدة، إصابة أو نزف في الدماغ، جراحة حديثة للدماغ أو العينين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية لمنع تجلط الدم (مثل الوارفارين، دبيجاتران، ابيكسابان أو هيبارين)، ما عدا عند تغيير العلاج المضاد للتجلط أو خلال استخدام الهيبارين عن طريق انبوب تسريب داخل الوريد أو الشريان لإبقائه مفتوحاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض في الكبد الذي يؤدي إلى زيادة نسبة الإصابة بنزيف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حامل أو مُرضع</p><p dir="RTL"><strong>لا تتناول ليبسا و ابلغ طبيبك</strong>&nbsp;إذا كان أي من هذه الحالات تنطبق عليك.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي قبل تناول <strong>ليبسا</strong>.</p><p dir="RTL"><strong>اتخذ عناية خاصة مع ليبسا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت عرضة للإصابة بنزيف، كما في الحالات الآتية:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكلى المعتدلة أو الحادة، لأن وظيفة الكلى قد تؤثر على كمية الدواء التي تعمل في جسمك</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية اخرى لمنع تجلط الدم (مثل الوارفارين، دبيجاتران، ابيكسابان أو هيبارين)، عندما يتم تغيير العلاج المضاد للتجلط أو خلال استخدام الهيبارين عن طريق انبوب تسريب داخل الوريد أو الشريان لإبقائه مفتوحاً (انظر الجزء &quot;تناول أدوية أخرى مع <strong>ليبسا</strong>&quot;)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اضطرابات نزف</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع جداً، وغير منضبط بعلاج طبي</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض المعدة أو الأمعاء التي قد تؤدي إلى النزف، على سبيل المثال التهاب الأمعاء أو المعدة، أو التهاب في المريء، على سبيل المثال بسبب مرض الارتداد المعدي المريئي (يحدث في هذا الحالة صعود حمض المعدة إلى المريء)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة بالأوعية الدموية خلف العيون (اعتلال الشبكية)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض في الرئة، يسبب اتساع للشعب الهوائية و تمتلئ بالصديد (توسع القصبات)، أو سبق تعرضك لنزيف من الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك صمام صناعي في القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أن لديك مرضاً يسمى متلازمة مضاد الفوسفوليبيد (اضطراب في الجهاز المناعي الذي يسبب زيادة نسبة الإصابة بتجلطات الدم) ، أخبر طبيبك الذي سيقرر ما إذا كان العلاج قد يحتاج إلى تغيير.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدد طبيبك أن ضغط الدم غير مستقر أو من المقرر تناول علاج آخر أو إجراء عملية جراحية لإزالة الدم المتجلط من الرئتين</p><p dir="RTL"><strong>أبلغ طبيبك قبل ان تتناول ليبسا</strong>، إذا كان اي من هذه الحالات تنطبق عليك. سوف يقرر طبيبك، إذا كان يجب أن تعالج بهذا الدواء و إذا كان يجب أن يبقيك تحت الملاحظة.</p><p dir="RTL"><strong>إذا كنت بحاجة لإجراء عملية جراحية</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جداً أن يتم تناول <strong>ليبسا</strong> قبل و بعد العملية الجراحية تماماً في الأوقات التي أوصي بها طبيبك&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت العملية تتضمن قسطرة أو حقن في العمود الفقري (مثل تخدير فوق الجافية أو النخاع الشوكي أو للحد من الألم):</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الهام جداً أن يتم تناول تماماً في الأوقات التي أوصي بها طبيبك</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فورا اذا كان لديك تنميل أو ضعف في الساقين أو مشاكل بالأمعاء أو المثانة بعد انتهاء التخدير، لأنه من الضروري وجود رعاية عاجلة.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى بتناول <strong>ليبسا</strong> لمن هم أقل من 18 سنة. لا توجد معلومات كافية عن استخدامه لدى الأطفال و المراهقين.</p><p dir="RTL"><strong>تناول أدوية أخرى مع ليبسا</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت حديثاً أو قد تتناول أية أدوية أخرى، بما فيها الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>إذا كنت تتناول</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية للعدوى الفطرية (مثل فلوكونازول، إيتراكونازول، فوريكونازول، بوزاكونازول)، إلا إذا وضعت فقط على الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الكيتوكونازول (المستخدمة لعلاج متلازمة كوشينغ - عندما ينتج الجسم فائض من الكورتيزول)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية العدوى البكتيرية (مثل كلاريثرومايسين وإريثروميسين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات لفيروس النقص المناعي البشري / الإيدز (متلازمة النقص المناعي المكتسب) HIV / AIDS (مثل ريتونافير)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لتقليل تجلط الدم (على سبيل المثال إنوكسابارين، كلوبيدوجرل أو مضادات فيتامين ك مثل الوارفارين و الاسينوكومارول)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مضادة للإلتهاب و مسكنة للألم (مثل نابروكسين أو حامض الاسيتيل ساليسيليك)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دروندارون، دواء لعلاج اضطراب نبضات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الاكتئاب (مثبطات امتصاص السيروتونين الانتقائية (SSRIs) أو مثبطات امتصاص النوربينفرين سيروتوني (SNRIs))</p><p dir="RTL"><strong>ابلغ طبيبك قبل استخدام ليبسا إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك</strong>، لأن تأثير <strong>ليبسا</strong> يمكن أن يزداد. سوف يقرر طبيبك، إذا كان يجب علاجك بـ<strong>ليبسا</strong> و إذا كان يجب أن يبقيك تحت الملاحظة.</p><p dir="RTL">إذا كان طبيبك يعتقد أن هناك خطورة حدوث قرح في المعدة أو في الأمعاء، يمكنه أيضاً استخدام علاج وقائي للقرحة.</p><p dir="RTL"><strong>إذا كنت تتناول</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الصرع (فنيتوين، كاربامازبين، فينوباربيتال).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة القديس جون، منتج نباتي يتم استخدامه لعلاج الاكتئاب.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبسين، مضاد حيوي.</p><p dir="RTL"><strong>ابلغ طبيبك قبل تناول ليبسا، إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك</strong>، لأن تأثير <strong>ليبسا</strong> يمكن أن يقل. سوف يقرر طبيبك، إذا كان يجب علاجك ب<strong>ليبسا</strong> و إذا كان يجب أن يبقيك تحت ملاحظة دقيقة.</p><p dir="RTL"><strong>تناول ليبسا مع الأطعمة والمشروبات</strong></p><p dir="RTL">&nbsp;يمكن تناول <strong>ليبسا</strong> مع أو بدون طعام.</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا تتناولي <strong>ليبسا</strong>، إذا كنتِ حامل أو مُرضع. إذا كان هناك احتمال بأن تصبحي حاملا، استخدمي مانع للحمل مضمون أثناء تناولك <strong>ليبسا</strong>. إذا أصبحتِ حاملا أثناء استخدامك <strong>ليبسا</strong>، فوراً أبلغي طبيبك الذي سوف يقرر كيف يجب علاجك</p><p dir="RTL"><strong>قيادة المركبات و استخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب <strong>ليبسا</strong> دوخة (شائعة) أو إغماء (غير شائعة) (أنظر القسم 4 &quot;الأعراض الجانبية المحتملة&quot;)<strong>.</strong></p><p dir="RTL">يجب عدم القيادة أو استخدام الآلات إذا عانيت من هذه الأعراض.</p><p dir="RTL"><strong>يحتوي </strong><strong>ليبسا</strong> <strong>على اللاكتوز والصوديوم</strong></p><p dir="RTL">إذا كان قد تم إبلاغك من قبل الطبيب أن لديك عدم احتمال لبعض السكريات، اتصل بطبيبك قبل تناول <strong>ليبسا</strong><strong>.</strong><br />يحتوي كل قرص من هذا الدواء على 0.262 من الصوديوم، وهذا يعني بشكل أساسي انه &quot;خالٍ من الصوديوم&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ليبسا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية للريفاروكسابان أو لأي من المكونات الأخرى في هذا الدواء (المدونة في الجزء 6)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنزف بإفراط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض أو حالة مرضية في أحد أعضاء الجسم تزيد من خطر النزف الحاد (مثال لذلك قرحة المعدة، إصابة أو نزف في الدماغ، جراحة حديثة للدماغ أو العينين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية لمنع تجلط الدم (مثل الوارفارين، دبيجاتران، ابيكسابان أو هيبارين)، ما عدا عند تغيير العلاج المضاد للتجلط أو خلال استخدام الهيبارين عن طريق انبوب تسريب داخل الوريد أو الشريان لإبقائه مفتوحاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض في الكبد الذي يؤدي إلى زيادة نسبة الإصابة بنزيف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حامل أو مُرضع</p><p dir="RTL"><strong>لا تتناول ليبسا و ابلغ طبيبك</strong>&nbsp;إذا كان أي من هذه الحالات تنطبق عليك.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي قبل تناول <strong>ليبسا</strong>.</p><p dir="RTL"><strong>اتخذ عناية خاصة مع ليبسا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت عرضة للإصابة بنزيف، كما في الحالات الآتية:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكلى المعتدلة أو الحادة، لأن وظيفة الكلى قد تؤثر على كمية الدواء التي تعمل في جسمك</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية اخرى لمنع تجلط الدم (مثل الوارفارين، دبيجاتران، ابيكسابان أو هيبارين)، عندما يتم تغيير العلاج المضاد للتجلط أو خلال استخدام الهيبارين عن طريق انبوب تسريب داخل الوريد أو الشريان لإبقائه مفتوحاً (انظر الجزء &quot;تناول أدوية أخرى مع <strong>ليبسا</strong>&quot;)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اضطرابات نزف</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع جداً، وغير منضبط بعلاج طبي</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض المعدة أو الأمعاء التي قد تؤدي إلى النزف، على سبيل المثال التهاب الأمعاء أو المعدة، أو التهاب في المريء، على سبيل المثال بسبب مرض الارتداد المعدي المريئي (يحدث في هذا الحالة صعود حمض المعدة إلى المريء)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة بالأوعية الدموية خلف العيون (اعتلال الشبكية)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض في الرئة، يسبب اتساع للشعب الهوائية و تمتلئ بالصديد (توسع القصبات)، أو سبق تعرضك لنزيف من الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك صمام صناعي في القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أن لديك مرضاً يسمى متلازمة مضاد الفوسفوليبيد (اضطراب في الجهاز المناعي الذي يسبب زيادة نسبة الإصابة بتجلطات الدم) ، أخبر طبيبك الذي سيقرر ما إذا كان العلاج قد يحتاج إلى تغيير.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدد طبيبك أن ضغط الدم غير مستقر أو من المقرر تناول علاج آخر أو إجراء عملية جراحية لإزالة الدم المتجلط من الرئتين</p><p dir="RTL"><strong>أبلغ طبيبك قبل ان تتناول ليبسا</strong>، إذا كان اي من هذه الحالات تنطبق عليك. سوف يقرر طبيبك، إذا كان يجب أن تعالج بهذا الدواء و إذا كان يجب أن يبقيك تحت الملاحظة.</p><p dir="RTL"><strong>إذا كنت بحاجة لإجراء عملية جراحية</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جداً أن يتم تناول <strong>ليبسا</strong> قبل و بعد العملية الجراحية تماماً في الأوقات التي أوصي بها طبيبك&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت العملية تتضمن قسطرة أو حقن في العمود الفقري (مثل تخدير فوق الجافية أو النخاع الشوكي أو للحد من الألم):</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الهام جداً أن يتم تناول تماماً في الأوقات التي أوصي بها طبيبك</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فورا اذا كان لديك تنميل أو ضعف في الساقين أو مشاكل بالأمعاء أو المثانة بعد انتهاء التخدير، لأنه من الضروري وجود رعاية عاجلة.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى بتناول <strong>ليبسا</strong> لمن هم أقل من 18 سنة. لا توجد معلومات كافية عن استخدامه لدى الأطفال و المراهقين.</p><p dir="RTL"><strong>تناول أدوية أخرى مع ليبسا</strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي إذا كنت تتناول أو قد تناولت حديثاً أو قد تتناول أية أدوية أخرى، بما فيها الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>إذا كنت تتناول</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية للعدوى الفطرية (مثل فلوكونازول، إيتراكونازول، فوريكونازول، بوزاكونازول)، إلا إذا وضعت فقط على الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الكيتوكونازول (المستخدمة لعلاج متلازمة كوشينغ - عندما ينتج الجسم فائض من الكورتيزول)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية العدوى البكتيرية (مثل كلاريثرومايسين وإريثروميسين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات لفيروس النقص المناعي البشري / الإيدز (متلازمة النقص المناعي المكتسب) HIV / AIDS (مثل ريتونافير)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لتقليل تجلط الدم (على سبيل المثال إنوكسابارين، كلوبيدوجرل أو مضادات فيتامين ك مثل الوارفارين و الاسينوكومارول)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مضادة للإلتهاب و مسكنة للألم (مثل نابروكسين أو حامض الاسيتيل ساليسيليك)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دروندارون، دواء لعلاج اضطراب نبضات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الاكتئاب (مثبطات امتصاص السيروتونين الانتقائية (SSRIs) أو مثبطات امتصاص النوربينفرين سيروتوني (SNRIs))</p><p dir="RTL"><strong>ابلغ طبيبك قبل استخدام ليبسا إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك</strong>، لأن تأثير <strong>ليبسا</strong> يمكن أن يزداد. سوف يقرر طبيبك، إذا كان يجب علاجك بـ<strong>ليبسا</strong> و إذا كان يجب أن يبقيك تحت الملاحظة.</p><p dir="RTL">إذا كان طبيبك يعتقد أن هناك خطورة حدوث قرح في المعدة أو في الأمعاء، يمكنه أيضاً استخدام علاج وقائي للقرحة.</p><p dir="RTL"><strong>إذا كنت تتناول</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الصرع (فنيتوين، كاربامازبين، فينوباربيتال).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة القديس جون، منتج نباتي يتم استخدامه لعلاج الاكتئاب.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبسين، مضاد حيوي.</p><p dir="RTL"><strong>ابلغ طبيبك قبل تناول ليبسا، إذا كان أي من الحالات المذكورة أعلاه تنطبق عليك</strong>، لأن تأثير <strong>ليبسا</strong> يمكن أن يقل. سوف يقرر طبيبك، إذا كان يجب علاجك ب<strong>ليبسا</strong> و إذا كان يجب أن يبقيك تحت ملاحظة دقيقة.</p><p dir="RTL"><strong>تناول ليبسا مع الأطعمة والمشروبات</strong></p><p dir="RTL">&nbsp;يمكن تناول <strong>ليبسا</strong> مع أو بدون طعام.</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا تتناولي <strong>ليبسا</strong>، إذا كنتِ حامل أو مُرضع. إذا كان هناك احتمال بأن تصبحي حاملا، استخدمي مانع للحمل مضمون أثناء تناولك <strong>ليبسا</strong>. إذا أصبحتِ حاملا أثناء استخدامك <strong>ليبسا</strong>، فوراً أبلغي طبيبك الذي سوف يقرر كيف يجب علاجك</p><p dir="RTL"><strong>قيادة المركبات و استخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب <strong>ليبسا</strong> دوخة (شائعة) أو إغماء (غير شائعة) (أنظر القسم 4 &quot;الأعراض الجانبية المحتملة&quot;)<strong>.</strong></p><p dir="RTL">يجب عدم القيادة أو استخدام الآلات إذا عانيت من هذه الأعراض.</p><p dir="RTL"><strong>يحتوي </strong><strong>ليبسا</strong> <strong>على اللاكتوز والصوديوم</strong></p><p dir="RTL">إذا كان قد تم إبلاغك من قبل الطبيب أن لديك عدم احتمال لبعض السكريات، اتصل بطبيبك قبل تناول <strong>ليبسا</strong><strong>.</strong><br />يحتوي كل قرص من هذا الدواء على 0.262 من الصوديوم، وهذا يعني بشكل أساسي انه &quot;خالٍ من الصوديوم&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كغيره من الأدوية يمكن أن يسبب بعض الأعراض الجانبية مع أنها لا تحدث لدى جميع الأشخاص. هذه الأعراض عادة ما تكون خفيفة إلى متوسطة بطبيعتها.</p><p dir="RTL">وكغيره من الأدوية الاخرى المشابهة لتقليل تشكل التجلطات الدموية، يمكن أن يسبب <strong>ليبسا</strong> نزيف والذي قد يكون مهدد للحياة. النزيف الحاد يمكن أن يؤدي لهبوط مفاجيء في ضغط الدم (صدمة). وفي بعض الحالات يمكن للنزيف أن يكون غير واضح.</p><p dir="RTL"><strong>أبلغ طبيبك فوراً&nbsp;إذا عانيت اي من الآثار الجانبية الآتية</strong><strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علامة لوجود نزيف</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخلي بالدماغ أو الجمجمة (أعراضه قد تشمل صداع، ضعف نصفي، قئ، تشنجات، انخفاض مستوى الوعي، وتصلب الرقبة. هذه حالة طبية حادة وطارئة وتتطلب تدخل طبي فوري!</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف لفترة طويلة أو مفرط (غزير)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف غير اعتيادي، تعب، شحوب، دوخة، صداع، تورم غير مبرر، صعوبة التنفس، ألم في الصدر أو ذبحة صدرية، التي يمكن أن تكون علامات للنزف،</p><p dir="RTL">ربما يقرر طبيبك أن يبقيك تحت الملاحظة الدقيقة أو يقوم بتغيير علاجك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علامة على رد فعل شديد في الجلد</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار طفح جلدي شديد، بثور أو تقرحات مخاطية، على سبيل المثال: في الفم أو العينين (متلازمة ستيفنز جونسون / انحلال البشرة السام).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل دوائي يسبب الطفح الجلدي والحمى والتهاب الأعضاء الداخلية والشذوذ الدموي والأمراض الجهازية (متلازمة DRESS)</p><p dir="RTL">معدل حدوث رد الفعل هذا نادر جدا (يصل إلى 1 في 10.000).</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>علامة على الحساسية الشديدة</strong></p><p dir="RTL"><strong>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورم في الوجه، الشفتين، الفم، اللسان أو الحلق؛ صعوبة في البلع؛ حكة موضعية وصعوبات في التنفس؛ انخفاض مفاجئ في ضغط الدم.</p><p dir="RTL">تكرار هذه الآثار الجانبية نادر جداً (ردود أفعال لحساسية، بما في ذلك صدمة الحساسية؛ يمكن أن تصل الإصابة إلى 1 في 10.000 شخص) وغير شائع (خَزَب وعائي وحساسية تورمية يمكن أن تصل الإصابة إلى 1 في 100 شخص)</p><p dir="RTL"><strong>قائمة بالأعراض الجانبية المحتملة</strong></p><p dir="RTL"><strong>شائعة</strong> (يؤثر على أكثر من أو يساوي 1 في 100 وأقل من 1 في 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء التي يمكن أن تجعل الجلد شاحب و تسبب ضعف أو صعوبة التنفس&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المعدة أو الأمعاء، نزيف في الجهاز البولي و التناسلي (تشمل دم في البول و نزيف طمثي)، نزيف بالانف، نزيف باللثة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل العين (يشمل نزيف من بياض العيون)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل نسيج أو تجويف في الجسم (تجمع دموي، كدمة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مصاحب لدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الجلد أو تحت الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بعد اجراء عملية جراحية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتشاح دم أو سائل من الجرح</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الاطراف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الاطراف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في وظائف الكلى (يمكن التعرف عليها في الاختبارات التي يؤديها الطبيب)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في درجة حرارة الجسم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة، عسر الهضم، شعور بالغثيان، إمساك، إسهال،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم منخفض (الأعراض يمكن أن تكون دوخة أو إغماء عند الوقوف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عام في المقدرة و الطاقة (ضعف، تعب)، صداع، دوخة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح، حكة جلدية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تُظهر اختبارات الدم زيادة في بعض إنزيمات الكبد</p><p dir="RTL"><strong>غير شائعة</strong> (يؤثر على أكثر من أو يساوي 1 في 1,000 و أقل من 1 في 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل المخ أو داخل الجمجمة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل المفصل يسبب ألم و ورم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الصفائح الدموية (انخفاض عدد الصفائح الدموية، وهي الخلايا التي تساعد على تجلط الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات أرجية (حساسية)، تشمل تفاعلات أرجية (حساسية) للجلد،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل وظائف الكبد (يمكن أن يظهر في الفحوصات المخبرية الذي يقوم بها طبيبك)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تُظهر اختبارات الدم زيادة في البيليروبين، بعض إنزيمات البنكرياس أو إنزيمات الكبد أو في عدد الصفائح الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور باعتلال الصحة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نبضات القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف بالفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى</p><p dir="RTL"><strong>نادرة (</strong>يؤثر على أكثر من أو يساوي 1 في 10,000 شخص وأقل من 1 في 1,000 شخص<strong>)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل العضل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ركود صفراوي (انخفاض تدفق الصفراء)، التهاب الكبد بما في ذلك إصابة الخلايا الكبدية (التهاب الكبد بما في ذلك إصابة الكبد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد و العين (يرقان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضعي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع دموي (ورم دموي) في الفخذ كمضاعفات لإجراءات قلبية تتطلب إدخال قسطرة (قثطار) داخل شريان الساق (تمدد كيسى دموى كاذب)</p><p dir="RTL"><strong>غير معروفة (</strong>لا يمكن تقدير معدلات أو وتيرة الحدوث من واقع البيانات المتوفرة<strong>)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي بعد نزيف شديد&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط &nbsp;داخل عضلات الساق أو الذراع بعد النزيف، و الذي يمكن أن يؤدي لألم، تورم، تغيير في الاحساس، تنميل أو شلل.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:317px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف الموحد: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية لكل دولة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول <strong>ليبسا</strong> بعد تاريخ انتهاء صلاحيته المطبوع على العلبة أو الشريطة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول <strong>ليبسا</strong> إذا لاحظت علامات تشوه العبوة أو علامات تمزق للعبوة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأقراص المسحوقة: ثابته بالماء أو التفاح المهروس لمدة 4 ساعات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم إلقاء أي أدوية في مياه الصرف الصحي أو في النفايات المنزلية. وعليك أن تسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاجها. وهذه التدابير تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي ليبسا</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد <strong>الفعالة</strong> هي ريفاروكسابان. يحتوي كل قرص على 10 ملجم ريفاروكسابان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات <strong>الأخرى</strong> هي:</p><p dir="RTL"><strong>▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>داخل القرص: </strong>لاكتوز وحيد التميّة، مايكروكريستالين سيليلوز، كروس كارميلوز الصوديوم، دوديسيل كبريتات الصوديوم، هايبروميلوز، إيتانول، سترات المغنيسيوم، ماء مُنَقّى.</p><p dir="RTL">▪&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غلاف القرص:</strong> انستا أكوا وردي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص ليبسا&nbsp; 10 ملجم المغلفة بطبقة رقيقة</strong> قرص دائري ثنائي التحدب مغطى بطبقة رقيقة، ذو اللون الوردي، منقوش&quot;JS51&quot; &nbsp;على أحد جانبيه.</p><p dir="RTL">تتوفر أقراص <strong>ليبسا&nbsp; 10 ملجم المغلفة بطبقة رقيقة</strong> في عبوات تحتوي على 30 قرص أو 10 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ألفا فارما</p><p dir="RTL">مدينة الملك عبد الله الإقتصادية، المملكة العربية السعودية</p><p dir="RTL">هاتف: 29013 21 12 966+</p><p dir="RTL">البريد الإلكتروني: regulatory@alphapharma.com.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            4/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LIBSA 10 mg Film-coated Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg of rivaroxaban.
Excipient with known effect
Each film-coated tablet contains 26.7 mg lactose (as monohydrate), see section 4.4.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)
Pink, round shaped, biconvex film-coated tablets, debossed JS51 on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for hemodynamically unstable PE patients.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</em></p><p>The recommended dose is 10 mg rivaroxaban taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that hemostasis has been established.</p><p>The duration of treatment depends on the individual risk of the patient for venous thromboembolism which is determined by the type of orthopedic surgery.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients undergoing major hip surgery, a treatment duration of 5 weeks is recommended.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients undergoing major knee surgery, a treatment duration of 2 weeks is recommended.</p><p>If a dose is missed the patient should take LIBSA immediately and then continue the following day with once daily intake as before.</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE</em></p><p>The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.</p><p>Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.</p><p>When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with <strong>LIBSA </strong>10 mg once daily, a dose of LIBSA 20 mg once daily should be considered.</p><p>The duration of therapy and dose selection should be individualized after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Time period</strong></p></td><td><p><strong>Dosing schedule</strong></p></td><td><p><strong>Total daily dose</strong></p></td></tr><tr><td rowspan="2"><p>Treatment and prevention of recurrent DVT and PE</p></td><td><p>Day 1-21</p></td><td><p>15 mg twice daily</p></td><td><p>30 mg</p></td></tr><tr><td><p>Day 22 onwards</p></td><td><p>20 mg once daily</p></td><td><p>20 mg</p></td></tr><tr><td><p>Prevention of recurrent DVT and PE</p></td><td><p>Following completion of at least 6 months therapy for DVT or PE</p></td><td><p>10 mg once daily or</p><p>20 mg once daily</p></td><td><p>10 mg</p><p>or 20 mg</p></td></tr></tbody></table><p>To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks&rsquo; treatment initiation pack of LIBSA for treatment of DVT/PE is available.</p><p>If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take LIBSA immediately to ensure intake of 30 mg LIBSA per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.</p><p>If a dose is missed during the once daily treatment phase, the patient should take LIBSA immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p><em>Converting from Vitamin K Antagonists (VKA) to LIBSA</em></p><p>For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and LIBSA therapy should be initiated once the INR is &le; 2.5.</p><p>When converting patients from VKAs to LIBSA, International Normalized Ratio (INR) values will be falsely elevated after the intake of LIBSA. The INR is not valid to measure the anticoagulant activity of LIBSA, and therefore should not be used (see section 4.5).</p><p><em>Converting from LIBSA to Vitamin K antagonists (VKA)</em></p><p>There is a potential for inadequate anticoagulation during the transition from LIBSA to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that LIBSA can contribute to an elevated INR.</p><p>In patients converting from LIBSA to VKA, VKA should be given concurrently until the INR is &ge; 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both LIBSA and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of LIBSA. Once LIBSA is discontinued INR testing may be done reliably at least 24hours after the last dose (see sections 4.5 and 5.2).</p><p><em>Converting from parenteral anticoagulants to LIBSA</em></p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start LIBSA 0 to2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p><em>Converting from LIBSA to parenteral anticoagulants</em></p><p>Give the first dose of parenteral anticoagulant at the time the next LIBSA dose would be taken.</p><p><em>Special populations</em></p><p><u>Renal Impairment</u></p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, LIBSA is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.4 and 5.2).</p><p>- For the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery, no dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30- 49 ml/min) (see section 5.2).</p><p>- For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE, no dose adjustment from the recommended dose is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).</p><p>In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient&#39;s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).</p><p>When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.</p><p><u>Hepatic impairment</u></p><p>LIBSA is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).</p><p><u>Elderly population</u></p><p>No dose adjustment (see section 5.2)</p><p><u>Body weight</u></p><p>No dose adjustment (see section 5.2)</p><p><u>Gender</u></p><p>No dose adjustment (see section 5.2)</p><p><u>Pediatric population</u></p><p>The safety and efficacy of LIBSA 10 mg tablets in children aged 0 to 18 years have not been established. No data are available. Therefore, LIBSA 10 mg tablets are not recommended for use in children below 18 years of age.</p><p><u>Method of Administration</u></p><p>LIBSA is for oral use.</p><p>The tablets can be taken with or without food (see sections 4.5 and 5.2).</p><p>Crushing of tablets</p><p>For patients who are unable to swallow whole tablets, LIBSA tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.</p><p>The crushed tablet may also be given through gastric tubes (see sections 5.2 and 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active clinically significant bleeding.
Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).
Pregnancy and breast-feeding (see section 4.6). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p><u>Hemorrhagic risk</u></p><p>As with other anticoagulants, patients taking LIBSA are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of hemorrhage. LIBSA administration should be discontinued if severe hemorrhage occurs (see section 4.9).</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genitourinary including abnormal vaginal or increased menstrual bleeding) and anemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of hemoglobin/hematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anemia after initiation of treatment (see section 4.8).</p><p>In patients receiving LIBSA<strong> </strong>for VTE prevention following elective hip or knee replacement surgery, this may be done by regular physical examination of the patients, close observation of the surgical wound drainage and periodic measurements of hemoglobin.</p><p>Any unexplained fall in hemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).</p><p><u>Renal impairment</u></p><p>In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. LIBSA is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.2 and 5.2).</p><p>In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations LIBSA is to be used with caution (see section 4.5).</p><p><u>Interaction with other medicinal products</u></p><p>The use of LIBSA is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting hemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).</p><p><u>Other hemorrhagic risk factors</u></p><p>As with other antithrombotic, rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; congenital or acquired bleeding disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrolled severe arterial hypertension</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, esophagitis, gastritis and gastroesophageal reflux disease)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vascular retinopathy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bronchiectasis or history of pulmonary bleeding</p><p><u>Patients with prosthetic valves</u></p><p>Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone trans catheter aortic valve replacement (TAVR). Safety and efficacy of LIBSA<strong> </strong>have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that LIBSA provides adequate anticoagulation in this patient population. Treatment with LIBSA is not recommended for these patients.</p><p><u>Patients with antiphospholipid syndrome</u></p><p>Direct acting Oral Anticoagulants (DOACs) including rivaroxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular, for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><u>Hip fracture surgery</u></p><p>Rivaroxaban has not been studied in interventional clinical studies in patients undergoing hip fracture surgery to evaluate efficacy and safety.</p><p>Hemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</p><p>LIBSA is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are hemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of LIBSA have not been established in these clinical situations.</p><p><u>Spinal/epidural anesthesia or puncture</u></p><p>When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.</p><p>To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low (see section 5.2).</p><p>At least 18 hours should elapse after the last administration of rivaroxaban before removal of an epidural catheter. Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.</p><p>If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.</p><p>Dosing recommendations before and after invasive procedures and surgical intervention other than elective hip or knee replacement surgery</p><p>If an invasive procedure or surgical intervention is required, LIBSA 10 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician.</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>LIBSA should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate hemostasis has been established as determined by the treating physician (see section5.2).</p><p><u>Elderly population</u></p><p>Increasing age may increase hemorrhagic risk (see section 5.2).</p><p><u>Dermatological reactions</u></p><p>Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p><p><u>Information about excipients</u></p><p>LIBSA contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>This medicinal product contains 0.262 mg sodium per dosage unit, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>CYP3A4 and P-gp inhibitors</u></p><p>Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6fold / 2.5-fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6-fold increase in mean rivaroxaban C<sub>max</sub>, with significant increases in pharmacodynamics effects which may lead to an increased bleeding risk. Therefore, the use of LIBSA is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).</p><p>Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5-fold increase in mean rivaroxaban AUC and a 1.4-fold increase in C<sub>max</sub>. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3-fold increase in mean rivaroxaban AUC and Cmax. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8-fold increase in mean rivaroxaban AUC and 1.6-fold increase in CR<sub>max </sub>when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0-fold increase in mean rivaroxaban AUC and 1.6-fold increase in CR<sub>max</sub> when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).</p><p>Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4-fold increase in mean rivaroxaban AUC and a 1.3-fold increase in mean Cmax. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.</p><p><u>Anticoagulants</u></p><p>After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).</p><p><u>NSAIDs/platelet aggregation inhibitors</u></p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamics response.</p><p>No clinically significant pharmacokinetic or pharmacodynamics interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.</p><p>Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).</p><p><u>SSRIs/SNRIs</u></p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.</p><p><u>Warfarin</u></p><p>Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.</p><p>If it is desired to test the pharmacodynamics effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Hep test can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.</p><p>If it is desired to test the pharmacodynamics effects of warfarin during the conversion period, INR measurement can be used at the C trough of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and rivaroxaban.</p><p><u>CYP3A4 inducers</u></p><p>Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamics effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort (Hypericumperforatum)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p><u>Other concomitant therapies</u></p><p>No clinically significant pharmacokinetic or pharmacodynamics interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms likeCYP3A4.</p><p>No clinically relevant interaction with food was observed (see section 4.2).</p><p><u>Laboratory parameters</u></p><p>Clotting parameters (e.g. PT, aPTT, Hep Test) are affected as expected by the mode of action of rivaroxaban (see section5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Safety and efficacy of LIBSA have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, LIBSA is contraindicated during pregnancy (see section 4.3).</p><p>Women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban.</p><p><u>Breast-feeding</u></p><p>Safety and efficacy of LIBSA have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore, LIBSA is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.</p><p><u>Fertility</u></p><p>No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LIBSA<strong> </strong>has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of rivaroxaban has been evaluated in thirteen phase III studies in adults including 53,103 patients exposed to rivaroxaban and in two phase II and one phase III pediatric studies including 412 patients. See phase III studies as listed in table 1.</p><p><strong>Table 1: Number of patients studied, total daily dose and maximum treatment duration in adult and pediatric phase III studies </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Number of patients*</strong></p></td><td><p><strong>Total daily dose</strong></p></td><td><p><strong>Maximum treatment duration</strong></p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE)in adult patients undergoing elective hip or knee replacement surgery</p></td><td><p>6,097</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>3,997</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>6,790</p></td><td><p>Day 1 - 21: 30 mg</p><p>Day 22 and onwards: 20mg</p><p>After at least 6 months: 10mg or 20 mg</p></td><td><p>21 months</p></td></tr><tr><td><p>Treatment of VTE and prevention of VTE recurrence in term neonates and children aged less than 18 years following initiation of standard anticoagulation treatment</p></td><td><p>329</p></td><td><p>Body weight-adjusted dose to achieve a similar exposure as that observed in adults treated for DVT with 20 mg rivaroxaban once daily</p></td><td><p>12 months</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism inpatients with non-valvular atrial fibrillation</p></td><td><p>7,750</p></td><td><p>20 mg</p></td><td><p>41 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events inpatients after an acute coronary syndrome(ACS)</p></td><td><p>10,225</p></td><td><p>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td><p>31 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>18,244</p></td><td><p>5 mg co-administered with ASA or 10 mg alone</p></td><td><p>47 months</p></td></tr></tbody></table><p>* Patients exposed to at least one dose of rivaroxaban</p><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and&#39; Description of selected adverse reactions&#39; below) (Table 2). The most commonly reported bleedings were epistaxis (4.5%) and gastrointestinal tract hemorrhage (3.8).</p><p><strong>Table 2: Bleeding* and anemia events rates in patients exposed to rivaroxaban across the completed adult and pediatric phase III studies.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Any bleeding</strong></p></td><td><p><strong>Anemia</strong></p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE)in adult patients undergoing elective hip or knee replacement surgery</p></td><td><p>6.8% of patients</p></td><td><p>5.9% of patients</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>12.6% of patients</p></td><td><p>2.1% of patients</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td style="vertical-align:top"><p>23% of patients</p></td><td style="vertical-align:top"><p>1.6% of patients</p></td></tr><tr><td><p>Treatment of VTE and prevention of VTE recurrence in term neonates and children aged less than 18 years following initiation of standard anticoagulation treatment</p></td><td style="vertical-align:top"><p>39.5% of patients</p></td><td style="vertical-align:top"><p>4.6% of patients</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism inpatients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>28 per 100 patient years</p></td><td style="vertical-align:top"><p>2.5 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events inpatients after an acute coronary syndrome(ACS)</p></td><td style="vertical-align:top"><p>22 per 100 patient years</p></td><td style="vertical-align:top"><p>1.4 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td style="vertical-align:top"><p>6.7 per 100 patient years</p></td><td style="vertical-align:top"><p>0.15 per 100 patient years</p></td></tr></tbody></table><p>* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.</p><p>** In the COMPASS study, there is a low anemia incidence as a selective approach to adverse event collection was applied</p><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions reported with LIBSA<strong> </strong>in adult and pediatric patients are summarized in Table 3below by system organ class (in MedDRA) and by frequency.</p><p><em>Frequencies are defined as:</em></p><p>very common (&ge; 1/10)</p><p>common (&ge; 1/100 to &lt; 1/10)</p><p>uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>very rare (&lt; 1/10,000)</p><p>not known (cannot be estimated from the available data)</p><p><strong>Table 3: All adverse reactions reported in adult patients in phase III clinical studies or through post-marketing use* and in two phase II and one phase III studies in pediatric patients.</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td colspan="5"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>Anemia (incl. respective laboratory parameters)</p></td><td><p>Anemia (incl. respective laboratory parameters)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Immune system disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Allergic reaction, dermatitis allergic, angioedema and allergic edema</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic reactions including anaphylactic shock</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness, headache</p></td><td style="vertical-align:top"><p>Dizziness, headache</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>Eye hemorrhage (incl. conjunctival hemorrhage)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tachycardia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Vascular disorders</strong></p></td></tr><tr><td><p>Hypotension, hematoma</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Epistaxis, hemoptysis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>Gingival bleeding, gastrointestinal tract hemorrhage (incl. rectal hemorrhage),gastrointestinal and abdominal pains, dyspepsia, nausea, constipation <sup>A</sup>, diarrhea, vomiting <sup>A</sup></p></td><td><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Hepatobiliary disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Increase in transaminases</p></td><td><p>Hepatic impairment, increased bilirubin ,increased blood alkaline phosphatase <sup>A</sup> ,increased GGT<sup>A</sup></p></td><td><p>Jaundice, bilirubin conjugated increased(with or without concomitant increase of ALT), cholestasis ,hepatitis (incl. hepatocellular injury)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus (incl. uncommon cases of generalized pruritus),rash, ecchymosis, cutaneous and subcutaneous hemorrhage</p></td><td><p>Urticaria</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome/Toxic Epidermal Necrolysis, DRESS syndrome</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pain in extremity <sup>A</sup></p></td><td><p>Haemarthrosis</p></td><td style="vertical-align:top"><p>Muscle hemorrhage</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urogenital tract hemorrhage (incl. hematuria and menorrhagia <sup>B</sup>), renal impairment (incl. blood creatinine increased, blood urea increased)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypo perfusion</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fever <sup>A</sup>, peripheral edema, decreased general strength and energy (incl. fatigue and asthenia)</p></td><td style="vertical-align:top"><p>Feeling unwell (incl. malaise)</p></td><td style="vertical-align:top"><p>Localized edema <sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Increased LDH<sup>A</sup>,</p><p>increased lipase <sup>A</sup>,</p><p>increased amylase <sup>A</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Post procedural hemorrhage (incl. post-operative anemia, and wound hemorrhage),contusion, wound secretion <sup>A</sup></p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vascular pseudo aneurysm <sup>C</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</p><p>* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.</p><p><u>Description of selected adverse reactions</u></p><p>Due to the pharmacological mode of action, the use of LIBSA may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post hemorrhagic anemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anemia (see section 4.9 &ldquo;Management of bleeding&rdquo;). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genitourinary including abnormal vaginal or increased menstrual bleeding) and anemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of hemoglobin/hematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting hemostasis (see section 4.4 &ldquo;Hemorrhagic risk&rdquo;). Menstrual bleeding may be intensified and/or prolonged. Hemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnea and unexplained shock. In some cases, as a consequence of anemia, symptoms of cardiac ischemia like chest pain or angina pectoris have been observed.</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypo perfusion have been reported for LIBSA. Therefore, the possibility of hemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><strong>To report any side effect(s): </strong></p><p>&sect;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:378px"><tbody><tr><td style="vertical-align:top"><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&sect;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above.</p><p>A specific reversal agent (andexanet alfa) antagonizing the pharmacodynamics effect of rivaroxaban is available (refer to the Summary of Product Characteristics of andexanet alfa).</p><p>The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.</p><p><u>Management of bleeding</u></p><p>Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualized according to the severity and location of the hemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical hemostasis with bleeding control procedures, fluid replacement and hemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anemia or coagulopathy) or platelets.</p><p>If bleeding cannot be controlled by the above measures, either the administration of a specific factor Xa inhibitor reversal agent (andexanet alfa), which antagonizes the pharmacodynamics effect of rivaroxaban, or a specific procoagulant reversal agent, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa), should be considered. However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).</p><p>Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic hemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialyzable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01</p><p><u>Mechanism of action</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p><u>Pharmacodynamics effects</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant. In patients undergoing major orthopedic surgery, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) ranged from 13 to 25 s (baseline values before surgery 12 to 15 s).</p><p>In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factorPCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).</p><p>The activated partial thromboplastin time (aPTT) and Hep Test are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamics effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).</p><p><u>Clinical efficacy and safety</u></p><p><em>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</em></p><p>The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban for the prevention of VTE, i.e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopedic surgery of the lower limbs. Over 9,500 patients (7,050 in total hip replacement surgery and 2,531 in total knee replacement surgery) were studied in controlled randomized double-blind phase III clinical studies, the RECORD-programme.</p><p>Rivaroxaban 10 mg once daily (od) started no sooner than 6 hours post-operatively was compared with enoxaparin 40mg once daily started 12 hours pre-operatively.</p><p>In all three phase III studies (see table 4), rivaroxaban significantly reduced the rate of total VTE (any veno graphically detected or symptomatic DVT, non-fatal PE and death) and major VTE (proximal DVT, non-fatal PE and VTE-related death), the pre-specified primary and major secondary efficacy endpoints. Furthermore, in all three studies the rate of symptomatic VTE (symptomatic DVT, non-fatal PE, VTE-related death) was lower in rivaroxaban treated patients compared to patients treated with enoxaparin.</p><p>The main safety endpoint, major bleeding, showed comparable rates for patients treated with rivaroxaban 10 mg compared to enoxaparin 40 mg.</p><p><strong>Table 4: Efficacy and safety results from phase III clinical studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="3"><p><strong>RECORD 1</strong></p></td><td colspan="3"><p><strong>RECORD 2</strong></p></td><td colspan="3"><p><strong>RECORD 3</strong></p></td></tr><tr><td><p><strong>Study population</strong></p></td><td colspan="3"><p><strong>4,541 patients undergoing total hip replacement surgery</strong></p></td><td colspan="3"><p><strong>2,509 patients undergoing total hip replacement surgery</strong></p></td><td colspan="3"><p><strong>2,531 patients undergoing total knee replacement surgery</strong></p></td></tr><tr><td><p>Treatment dose and duration after surgery</p></td><td><p>Rivaroxaban</p><p>10 mg od</p><p>35 &plusmn; 4 days</p></td><td><p>Enoxaparin</p><p>40 mg od</p><p>35 &plusmn; 4days</p></td><td><p>p</p></td><td><p>Rivaroxaban</p><p>10 mg od</p><p>35 &plusmn; 4 days</p></td><td><p>Enoxaparin</p><p>40 mg od</p><p>12 &plusmn; 2 days</p></td><td><p>p</p></td><td><p>Rivaroxaban</p><p>10 mg od</p><p>12 &plusmn; 2 days</p></td><td><p>Enoxaparin</p><p>40 mg od</p><p>12 &plusmn; 2days</p></td><td><p>p</p></td></tr><tr><td><p>Total VTE</p></td><td><p>18 (1.1%)</p></td><td><p>58 (3.7%)</p></td><td><p>&lt; 0.001</p></td><td><p>17 (2.0%)</p></td><td><p>81 (9.3%)</p></td><td><p>&lt; 0.001</p></td><td><p>79 (9.6%)</p></td><td><p>166(18.9%)</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Major VTE</p></td><td><p>4 (0.2%)</p></td><td><p>33 (2.0%)</p></td><td><p>&lt; 0.001</p></td><td><p>6 (0.6%)</p></td><td><p>49 (5.1%)</p></td><td><p>&lt; 0.001</p></td><td><p>9 (1.0%)</p></td><td><p>24 (2.6%)</p></td><td><p>0.01</p></td></tr><tr><td><p>Symptomatic VTE</p></td><td><p>6 (0.4%)</p></td><td><p>11 (0.7%)</p></td><td><p>&nbsp;</p></td><td><p>3 (0.4%)</p></td><td><p>15 (1.7%)</p></td><td><p>&nbsp;</p></td><td><p>8 (1.0%)</p></td><td><p>24 (2.7%)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Major bleedings</p></td><td><p>6 (0.3%)</p></td><td><p>2 (0.1%)</p></td><td><p>&nbsp;</p></td><td><p>1 (0.1%)</p></td><td><p>1 (0.1%)</p></td><td><p>&nbsp;</p></td><td><p>7 (0.6%)</p></td><td><p>6 (0.5%)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>The analysis of the pooled results of the phase III studies corroborated the data obtained in the individual studies regarding reduction of total VTE, major VTE and symptomatic VTE with rivaroxaban 10 mg once daily compared to enoxaparin 40 mg once daily.</p><p>In addition to the phase III RECORD programmer, a post-authorization, non-interventional, open-label cohort study(XAMOS) has been conducted in 17,413 patients undergoing major orthopedic surgery of the hip or knee, to compare rivaroxaban with other pharmacological thromboprophylaxis (standard-of-care) under real-life setting. Symptomatic VTE</p><p>occurred in 57 (0.6%) patients in the rivaroxaban group (n=8,778) and 88 (1.0%) of patients in the standard-of-care group (n=8,635; HR 0.63; 95% CI 0.43-0.91); safety population). Major bleeding occurred in 35 (0.4%) and 29 (0.3%) of patients in the rivaroxaban and standard-of-care groups (HR 1.10; 95% CI 0.67-1.80). Thus, the results were consistent with the results of the pivotal randomized studies.</p><p><em>Treatment of DVT, PE and prevention of recurrent DVT and PE</em></p><p>The rivaroxaban clinical programmer was designed to demonstrate the efficacy of rivaroxaban in the initial and continued treatment of acute DVT and PE and prevention of recurrence.</p><p>Over 12,800 patients were studied in four randomized controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice). and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.</p><p>In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial 3-week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20mg rivaroxaban once daily.</p><p>In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.</p><p>In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (&ge; 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.</p><p>In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Rivaroxaban 20 mg once daily was compared with placebo.</p><p>Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.</p><p>In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomization date (median: 351 days). Rivaroxaban 20 mg once daily and rivaroxaban 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.</p><p>The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.</p><p>In the Einstein DVT study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p &lt; 0.0001 (test for non-inferiority); Hazard Ratio (HR): 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The pre specified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favor of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean center TTR (Time in Target INR Range of 2.0 &ndash; 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to center, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.</p><p><strong>Table 5: Efficacy and safety results from phase III Einstein DVT</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="2"><p><strong>3,449 patients with symptomatic acute deep vein thrombosis</strong></p></td></tr><tr><td><p><strong>Treatment dose and duration</strong></p></td><td><p><strong>Rivaroxaban a)</strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=1,731</strong></p></td><td><p><strong>Enoxaparin/VKA<sup>b</sup>)</strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=1,718</strong></p></td></tr><tr><td><p>Symptomatic recurrent VTE*</p></td><td><p>36</p><p>(2.1%)</p></td><td><p>51</p><p>(3.0%)</p></td></tr><tr><td><p>Symptomatic recurrent PE</p></td><td><p>20</p><p>(1.2%)</p></td><td><p>18</p><p>(1.0%)</p></td></tr><tr><td><p>Symptomatic recurrent DVT</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>28</p><p>(1.6%)</p></td></tr><tr><td><p>Symptomatic PE and DVT</p></td><td><p>1</p><p>(0.1%)</p></td><td><p>0</p></td></tr><tr><td><p>Fatal PE/death where PE cannot be ruled out</p></td><td><p>4</p><p>(0.2%)</p></td><td><p>6</p><p>(0.3%)</p></td></tr><tr><td><p>Major or clinically relevant non-major bleeding</p></td><td><p>139</p><p>(8.1%)</p></td><td><p>138</p><p>(8.1%)</p></td></tr><tr><td><p>Major bleeding events</p></td><td><p>14</p><p>(0.8%)</p></td><td><p>20</p><p>(1.2%)</p></td></tr><tr><td colspan="3"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>* </strong>p &lt; 0.0001 (non-inferiority to a pre specified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)</p></td></tr></tbody></table><p>In the Einstein PE study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 &ndash; 1.684)). The pre specified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139),nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean center TTR (Time in Target INR Range of 2.0 &ndash; 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082for interaction). Within the highest tertile according to center, the HR with rivaroxaban versus warfarin was 0.642 (95%CI: 0.277 - 1.484).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4%(274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).</p><p><strong>Table 6: Efficacy and safety results from phase III Einstein PE</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>4,832 patients with an acute symptomatic PE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban a)</strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=2,419</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin/VKA<sup>b</sup>)</strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=2,413</strong></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>50</p><p>(2.1%)</p></td><td style="vertical-align:top"><p>44</p><p>(1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>23</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>20</p><p>(0.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>18</p><p>(0.7%)</p></td><td style="vertical-align:top"><p>17</p><p>(0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic PE and DVT</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>11</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>7</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Major or clinically relevant non-major bleeding</p></td><td style="vertical-align:top"><p>249</p><p>(10.3%)</p></td><td style="vertical-align:top"><p>274</p><p>(11.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>26</p><p>(1.1%)</p></td><td style="vertical-align:top"><p>52</p><p>(2.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p>* p &lt; 0.0026 (non-inferiority to a pre specified HR of 2.0); HR: 1.123 (0.749 &ndash; 1.684)</p></td></tr></tbody></table><p>A pre specified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 7).</p><p><strong>Table 7: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>8,281 patients with an acute symptomatic DVT or PE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban a)</strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=4,150</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin/VKA<sup>b</sup>)</strong></p><p><strong>3, 6 or 12 months</strong></p><p><strong>N=4,131</strong></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>86</p><p>(2.1%)</p></td><td style="vertical-align:top"><p>95</p><p>(2.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>43</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>38</p><p>(0.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>32</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>45</p><p>(1.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic PE and DVT</p></td><td style="vertical-align:top"><p>1</p><p>(&lt;0.1%)</p></td><td style="vertical-align:top"><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>15</p><p>(0.4%)</p></td><td style="vertical-align:top"><p>13</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Major or clinically relevant non-major bleeding</p></td><td style="vertical-align:top"><p>388</p><p>(9.4%)</p></td><td style="vertical-align:top"><p>412</p><p>(10.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>40</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>72</p><p>(1.7%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b) Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>* </strong>p &lt; 0.0001 (non-inferiority to a pre specified HR of 1.75); HR: 0.886 (0.661 &ndash; 1.186)</p></td></tr></tbody></table><p>The pre specified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 &ndash; 0.967), nominal p value p = 0.0244).</p><p>In the Einstein Extension study (see Table 8) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.</p><p><strong>Table 8: Efficacy and safety results from phase III Einstein Extension</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban a)</strong></p><p><strong>6 or 12 months</strong></p><p><strong>N=602</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>6 or 12 months</strong></p><p><strong>N=594</strong></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>8</p><p>(1.3%)</p></td><td style="vertical-align:top"><p>42</p><p>(7.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>2</p><p>(0.3%)</p></td><td style="vertical-align:top"><p>13</p><p>(2.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>5</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>31</p><p>(5.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>1</p><p>(0.2%)</p></td><td style="vertical-align:top"><p>1</p><p>(0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>4</p><p>(0.7%)</p></td><td style="vertical-align:top"><p>0</p><p>(0.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinically relevant non-major bleeding</p></td><td style="vertical-align:top"><p>32</p><p>(5.4%)</p></td><td style="vertical-align:top"><p>7</p><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 20 mg once daily</p><p><strong>* </strong>p &lt; 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)</p></td></tr></tbody></table><p>In the Einstein Choice study (Table 9) rivaroxaban 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with rivaroxaban 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.</p><p><strong>Table 9: Efficacy and safety results from phase III Einstein Choice</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>3,396 patients continued prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment dose</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban 20 mg once daily</strong></p><p><strong>N=1,107</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban 10 mg once daily</strong></p><p><strong>N=1,127</strong></p></td><td style="vertical-align:top"><p><strong>ASA 100 mg once daily</strong></p><p><strong>N=1,131</strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment duration median[interquartile range]</p></td><td style="vertical-align:top"><p>349 [189-362] days</p></td><td style="vertical-align:top"><p>353 [190-362] days</p></td><td style="vertical-align:top"><p>350 [186-362] days</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE</p></td><td style="vertical-align:top"><p>17</p><p>(1.5%)*</p></td><td style="vertical-align:top"><p>13</p><p>(1.2%)**</p></td><td style="vertical-align:top"><p>50</p><p>(4.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>6</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>6</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>19</p><p>(1.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>9</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>8</p><p>(0.7%)</p></td><td style="vertical-align:top"><p>30</p><p>(2.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>2</p><p>(0.2%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p><p>(0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</p></td><td style="vertical-align:top"><p>19</p><p>(1.7%)</p></td><td style="vertical-align:top"><p>18</p><p>(1.6%)</p></td><td style="vertical-align:top"><p>56</p><p>(5.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>6</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>5</p><p>(0.4%)</p></td><td style="vertical-align:top"><p>3</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinically relevant non-major bleeding</p></td><td style="vertical-align:top"><p>30</p><p>(2.7)</p></td><td style="vertical-align:top"><p>22</p><p>(2.0)</p></td><td style="vertical-align:top"><p>20</p><p>(1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</p></td><td style="vertical-align:top"><p>23</p><p>(2.1%)+</p></td><td style="vertical-align:top"><p>17</p><p>(1.5%)++</p></td><td style="vertical-align:top"><p>53</p><p>(4.7%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* p&lt;0.001(superiority) rivaroxaban 20 mg od vs ASA 100 mg od; HR=0.34 (0.20&ndash;0.59)</p><p>** p&lt;0.001 (superiority) rivaroxaban 10 mg od vs ASA 100 mg od; HR=0.26 (0.14&ndash;0.47)</p><p>+ Rivaroxaban 20 mg od vs ASA 100 mg od; HR=0.44 (0.27&ndash;0.71), p=0.0009 (nominal)</p><p>++ Rivaroxaban 10 mg od vs ASA 100 mg od; HR=0.32 (0.18&ndash;0.55), p&lt;0.0001 (nominal)</p></td></tr></tbody></table><p>In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA)with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 -1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively.</p><p>These results in clinical practice are consistent with the established safety profile in this indication.</p><p>Patients with high risk triple positive antiphospholipid syndrome</p><p>In an investigator sponsored, randomized open-label multicenter study with blinded endpoint adjudication, rivaroxaban was compared to warfarin in patients with a history of thrombosis, diagnosed with antiphospholipid syndrome and at high risk for thromboembolic events (positive for all 3 antiphospholipid tests: lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies). The study was terminated prematurely after the enrolment of 120 patients due to an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. 59 patients were randomized to rivaroxaban 20 mg (15 mg for patients with creatinine clearance (CrCl) &lt; 50 mL/min) and 61 to warfarin (INR 2.0-3.0). Thromboembolic events occurred in 12% of patients randomized to rivaroxaban (4 ischemic strokes and3 myocardial infarctions). No events were reported in patients randomized to warfarin. Major bleeding occurred in 4patients (7%) of the rivaroxaban group and 2 patients (3%) of the warfarin group.</p><p><u>Pediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with LIBSA<strong> </strong>in all subsets of the pediatric population in the prevention of thromboembolic events (see section 4.2 for information on pediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (Cmax) appearing 2 - 4 hours after tablet intake.</p><p>Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or Cmax at the 2.5mg and 10 mg dose. Rivaroxaban 2.5 mg and 10 mg tablets can be taken with or without food. Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose. This is more marked in fasting state than in fed state. Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%, apart from on the day of surgery and the following day when variability in exposure is high (70%).</p><p>Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and Cmax compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.</p><p>Bioavailability (AUC and Cmax) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.</p><p><u>Distribution</u></p><p>Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with Vss being approximately 50 liters.</p><p><u>Biotransformation and elimination</u></p><p>Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolized via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of themorpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on <em>in vitro </em>investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p><u>Special populations</u></p><p><em>Gender</em></p><p>There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.</p><p><em>Elderly population</em></p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p><em>Different weight categories</em></p><p>Extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.</p><p><em>Inter-ethnic differences</em></p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.</p><p><em>Hepatic impairment</em></p><p>Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2-fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.</p><p>Rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p><em>Renal impairment</em></p><p>There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations(AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamics effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding rivaroxaban is not expected to be dialyzable.</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Rivaroxaban is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p><u>Pharmacokinetic data in patients</u></p><p>In patients receiving rivaroxaban for prevention of VTE 10 mg once daily the geometric mean concentration (90%prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 101 (7 - 273) and 14 (4 ‑ 51) mcg/l, respectively.</p><p><u>Pharmacokinetic/pharmacodynamics relationship</u></p><p>The pharmacokinetic/pharmacodynamics (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Hep test) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an E<sub>max</sub> model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/ (100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects. In patients, baseline factor Xa and PT were influenced by the surgery resulting in a difference in the concentration-PT slope between the day post-surgery and steady state.</p><p><u>Pediatric population</u></p><p>Safety and efficacy have not been established in the indication primary prevention of VTE for children and adolescents up to 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamics activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. hemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light colored spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Sodium lauryl sulphate</p><p>Hypromellose</p><p>Magnesium stearate</p><p>Ethyl alcohol</p><p>Purified water</p><p>Instacoat aqua pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (24 Months). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pink, round shaped, biconvex film-coated tablets, debossed JS51 on one side and plain on other side. Available in two pack sizes either containing 30 tablets or 10 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements, Keep out of the reach &amp; sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alpha Pharma, 
Kingdom of Saudi Arabia, Rabigh
P.O. Box 23989-6704
Tel: +966 12 21 29013
For any information about this medicinal product, please contact the Regulatory affairs department of authorization holder: 
Regulatory affairs department 
Riyadh, Saudi Arabia 
Tel: +966112931722 Ex:102 - 104
Email: regulatory@alphapharma.com.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23/08/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>